Active — Not RecruitingPhase 2

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

China65 participantsStarted 2025-10-01

Plain-language summary

In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with Cyclophosphamide,Vincristine,Prednisoneacetatetablets is planned to be used.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Hematology test standards:
✓. ANC ≥ 1.0 × 10\^9/L
✓. PLT ≥ 75 × 10\^9/L (for patients with confirmed bone marrow involvement: ≥ 50 × 10\^9/L)
✓. Hb ≥ 80 g/L
✓. Biochemistry test standards:
✓. TBIL \< 2 × ULN
✓. ALT and AST \< 2.5 × ULN (for patients with liver involvement, ALT and AST \< 5 × ULN)
✓. Endogenous creatinine clearance ≥ 40 ml/min (Cockcroft-Gault formula)

What they're measuring

24-month complete remission rate

Timeframe: From enrollment to 24 months

Trial details

NCT IDNCT07480863

SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-10-01

View on ClinicalTrials.gov More Marginal Zone Lymphoma(MZL) trials